drugset / Trial / NCT04725331
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
Phase 1/2
Terminated
31 enrolled
Transgene
BioInvent International AB · collabMerck Sharp & Dohme LLC · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
Timeline
- Start
- 2021-02-25
- Primary completion
- 2025-10-22
- Completion
- 2025-10-22
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision following completion of Phase I part not driven by safety reason”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BT-001 | Unknown | — | Other |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |